Therapeutic genome editing: prospects and challenges.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25654603.
- Also identified by DOI 10.1038/nm.3793 and PMC identifier 4492683.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent advances in the development of genome editing technologies based on programmable nucleases have substantially improved our ability to make precise changes in the genomes of eukaryotic cells. Genome editing is already broadening our ability to elucidate the contribution of genetics to disease by facilitating the creation of more accurate cellular and animal models of pathological processes. A particularly tantalizing application of programmable nucleases is the potential to directly correct genetic mutations in affected tissues and cells to treat diseases that are refractory to traditional therapies. Here we discuss current progress toward developing programmable nuclease-based therapies as well as future prospects and challenges.
Medical subject headings
- Endodeoxyribonucleases
- Genetic Therapy